CN113244367A - Medicated diet for people with hyperlipidemia - Google Patents

Medicated diet for people with hyperlipidemia Download PDF

Info

Publication number
CN113244367A
CN113244367A CN202110611871.7A CN202110611871A CN113244367A CN 113244367 A CN113244367 A CN 113244367A CN 202110611871 A CN202110611871 A CN 202110611871A CN 113244367 A CN113244367 A CN 113244367A
Authority
CN
China
Prior art keywords
parts
vitamin
hyperlipidemia
medicated diet
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110611871.7A
Other languages
Chinese (zh)
Inventor
于国耀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhao Tian
Original Assignee
Shanxingtianxia Jilin Technology Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanxingtianxia Jilin Technology Development Co ltd filed Critical Shanxingtianxia Jilin Technology Development Co ltd
Priority to CN202110611871.7A priority Critical patent/CN113244367A/en
Publication of CN113244367A publication Critical patent/CN113244367A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535—Perilla (beefsteak plant)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A medicated diet for people with hyperlipidemia, which relates to the field of medicated diet and solves the problems of the prior several hyperlipidemia treatment schemes. The invention comprises the following components in parts by weight: 1000-5000 parts of hawthorn, 1000-3000 parts of sea buckthorn, 1000-5000 parts of wolfberry fruit, 1000-3000 parts of astragalus membranaceus, 1000-2000 parts of chrysanthemum, 1000-3000 parts of ginkgo seed, 1000-3000 parts of purslane, 1000-3000 parts of purple perilla, 1000-5000 parts of red yeast rice, 1000-3000 parts of alpha-linolenic acid, 1000-3000 parts of conjugated linoleic acid, 5000-10000 parts of soybean protein, 1000-3000 parts of soybean lecithin, 500-1000 parts of vitamin C and 200-500 parts of vitamin E. The invention can nourish liver and kidney, invigorate spleen and stomach, suppress liver yang, clear heat and eliminate phlegm, promote qi circulation and remove blood stasis, resolve turbidity and reduce blood fat; inhibiting lipid deposition in liver, promoting lipid metabolism, inhibiting formation of atherosclerotic plaque, and protecting vascular endothelial cells; eliminating risk factors causing dyslipidemia, reducing the occurrence of atherosclerosis and reducing the incidence of hyperlipidemia complications.

Description

Medicated diet for people with hyperlipidemia
Technical Field
The invention relates to a medicated diet, in particular to a medicated diet for people with hyperlipidemia.
Background
Dyslipidemia, particularly the increase of serum cholesterol and low density lipoprotein cholesterol, and the decrease of high density lipoprotein cholesterol are the main risk factors for the development of atherosclerosis and the increased risk factors for coronary events in patients with coronary heart disease.
First, Chinese traditional treatment
Although TCM has no disease name of abnormal blood fat, there are some similar records in medical books of all ages. According to the characteristics of dyslipidemia, which is mainly manifested as symptoms of heavy limbs, dizziness and the like, modern doctors refer to it as "phlegm syndrome", "damp obstruction", "obstruction of qi in the chest", "vertigo" and the like.
Dyslipidemia belongs to the disease of both principal deficiency and secondary excess from the perspective of the Chinese medical syndrome. The deficient impairment of spleen, stomach, heart and liver is marked by turbid phlegm and blood stasis. For this syndrome, the patients should be treated by typing according to their different syndromes.
1. Internal retention of damp-heat
The syndrome is characterized in that: heavy head, fatigue, vexation, dizziness, blurred vision, abdominal distention, anorexia, dry mouth, bitter taste, loose stool, foul smell, yellow and turbid urine, phlegm nodule in skin and eyelid, orange yellow color, reddish tongue with yellow, turbid greasy tongue coating, and slippery and rapid pulse.
Therapeutic method: clear heat, resolve dampness, move qi and relieve stagnation.
2. Spleen deficiency with excessive dampness
The syndrome is characterized in that: heavy head, fatigue, abdominal distention, anorexia, asthenia, no desire to speak, pale and no thirst, loose stool, clear and profuse urine, amnesia, lusterless complexion, edema of the lower limbs, puffy eyelid, numbness of limbs, pale and swollen tongue with teeth marks, white and turbid tongue coating, and weak pulse.
Therapeutic method: to replenish qi, invigorate the spleen, harmonize the stomach and excrete dampness.
3. Stagnation of phlegm-turbidity
The syndrome is characterized in that: dizziness, heaviness of the head, nebula, nausea, vomiting, anorexia, abdominal distension, cough, sputum, obesity, slow reaction, heavy limbs, mass in the hypochondrium, greasy and thick tongue coating, and wiry and smooth pulse.
Therapeutic method: move qi and remove phlegm, invigorate spleen and harmonize stomach.
4. Qi stagnation and blood stasis
The syndrome is characterized in that: nebula and heart pain, fixed pain, dizziness and headache, or neck stiffness and numbness, dark and red tongue, or petechia and petechia, sublingual collaterals tortuosity, wiry or unsmooth pulse.
Therapeutic method: to soothe the liver, regulate qi, activate blood and dredge vessels.
5. Deficiency of kidney essence
The syndrome is characterized in that: dizziness, headache, insomnia, amnesia, alopecia, shaking teeth, tinnitus, deafness, slow movement, clumsy movements, dull spirit or swollen limbs, pale and dark tongue with thin and white coating, deep and weak pulse, and even ulnar region.
Therapeutic method: tonify kidney essence and fill brain marrow.
6. Hyperactivity of yang due to yin deficiency
The syndrome is characterized in that: vertigo, headache, dysphoria, irritability, insomnia, dreaminess, soreness and weakness of waist and knees, tinnitus, dryness-sensation of the eyes, dysphoria with feverish sensation in the chest, night sweat, numbness of limbs, red tongue with little coating, poor fluid or no coating, and wiry, thready and rapid pulse.
Therapeutic method: to nourish yin, tonify kidney, pacify liver and subdue yang.
Other treatments
The clinical commonly used Chinese patent medicines are: zhibituo tablet, gynostemma pentaphylla total glycoside tablet, blood fat reducing capsule, dantian blood fat reducing pill, antilipemic tablet, etc.
Because the traditional Chinese medicine emphasizes dialectical treatment, patients with dyslipidemia in early and middle stages often have no symptoms or characteristic symptoms, and the prevention and treatment effects of the disease are affected by the condition that patients with dyslipidemia have no symptoms or symptoms which are difficult to distinguish.
Second and western medicine treatment
Dyslipidemia is a predisposing factor for atherosclerosis, a risk factor for cardiovascular and cerebrovascular diseases. Therefore, the primary purpose of treating dyslipidemia is to prevent and treat ischemic cardiovascular diseases.
1. Medical treatment
Hydroxymethyl glutaryl-coenzyme a reductase inhibitors (statins): simvastatin, lovastatin, pravastatin, atorvastatin, and the like;
② phenoxy aromatic acids (fibrates): fenofibrate, bezafibrate, and the like;
③ nicotinic acid and derivatives thereof: nicotinic acid, acipimox, and the like;
bile acid sequestrant (resinous): cholestyramine, colestipol, and the like;
fifthly, other: ezetimibe, probucol, n-3 fatty acid preparation, etc.
2. Other therapeutic measures
(1) Plasma purification treatment: only for severe refractory property with extreme sensitivity or intolerance to statins
Hypercholesterolemia;
(2) and (3) surgical treatment: comprises partial ileum end section resection, portal vein shunt and liver transplantation, etc.,
are not used basically.
(3) Gene therapy: the prior art is not mature.
Dyslipidemia combined with atherosclerosis is a complex pathological process, has more influence factors, is particularly easy to develop into atherosclerosis, and has no ideal method for preventing and treating atherosclerosis in western medicine at present.
Disclosure of Invention
In order to solve a plurality of problems of the traditional Chinese medicine and the western medicine in treating the hyperlipemia disease, the invention provides a medicated diet for people with hyperlipemia to eat.
The technical scheme adopted by the invention for solving the technical problem is as follows:
the invention relates to a medicated diet for hyperlipemia crowds, which comprises the following components in parts by weight:
1000-5000 parts of hawthorn, 1000-3000 parts of sea buckthorn, 1000-5000 parts of wolfberry fruit, 1000-3000 parts of astragalus membranaceus, 1000-2000 parts of chrysanthemum, 1000-3000 parts of ginkgo seed, 1000-3000 parts of purslane, 1000-3000 parts of purple perilla, 1000-5000 parts of red yeast rice, 1000-3000 parts of alpha-linolenic acid, 1000-3000 parts of conjugated linoleic acid, 5000-10000 parts of soybean protein, 1000-3000 parts of soybean lecithin, 500-1000 parts of vitamin C and 200-500 parts of vitamin E.
As a preferred embodiment, the medicated diet for the hyperlipemia population comprises the following components in parts by weight:
2000 parts of hawthorn, 1500 parts of sea buckthorn, 2000 parts of medlar, 1500 parts of astragalus, 1000 parts of chrysanthemum, 1500 parts of ginkgo, 1500 parts of purslane, 1500 parts of purple perilla, 2000 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1500 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1500 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
The invention has the beneficial effects that: the invention is composed of food and medicine substances such as hawthorn, sea backthern, medlar, astragalus, chrysanthemum, ginkgo, purslane, perilla and the like, and the combination of the products has the functions of nourishing liver and kidney, strengthening spleen and nourishing stomach, calming liver yang, clearing heat and eliminating phlegm, promoting qi circulation and removing blood stasis, and dissolving turbidity and reducing blood fat; the accurate nutrition strengthening part consists of red yeast rice, alpha-linolenic acid, conjugated linoleic acid, soybean protein, soybean lecithin and the like, and can inhibit lipid deposition in liver, promote lipid metabolism, inhibit formation of atherosclerotic plaque and protect vascular endothelial cells.
Clinical verification for over ten years proves that the medicinal diet for the hyperlipemia population can eliminate the risk factors causing dyslipidemia, reduce the occurrence of atherosclerosis and reduce the incidence of hyperlipidemia complications.
In addition, the edible and medicinal substances and the nutrition-enriched substances used in the invention are safe and have no toxic or side effect.
Detailed Description
The invention relates to a medicated diet for hyperlipemia crowds, which comprises the following components in parts by weight:
1000-5000 parts of hawthorn, 1000-3000 parts of sea buckthorn, 1000-5000 parts of wolfberry fruit, 1000-3000 parts of astragalus membranaceus, 1000-2000 parts of chrysanthemum, 1000-3000 parts of ginkgo seed, 1000-3000 parts of purslane, 1000-3000 parts of purple perilla, 1000-5000 parts of red yeast rice, 1000-3000 parts of alpha-linolenic acid, 1000-3000 parts of conjugated linoleic acid, 5000-10000 parts of soybean protein, 1000-3000 parts of soybean lecithin, 500-1000 parts of vitamin C and 200-500 parts of vitamin E.
The functions and effects of the components of the invention are as follows:
the invention is composed of food and medicine substances such as hawthorn, sea buckthorn, medlar, astragalus, chrysanthemum, ginkgo, purslane, perilla and the like, and the combination of the food and medicine substances has the functions of nourishing liver and kidney, strengthening spleen and nourishing stomach, calming liver yang, clearing heat and eliminating phlegm, promoting qi circulation and removing blood stasis, and dissolving turbidity and reducing blood fat.
The invention uses red yeast rice, alpha-linolenic acid, conjugated linoleic acid, soybean protein, soybean lecithin and the like to form an accurate nutrition strengthening part, and can inhibit lipid deposition in liver, promote lipid metabolism, inhibit formation of atherosclerotic plaque and protect vascular endothelial cells.
The preparation method of the medicated diet for the hyperlipemia population specifically comprises the following steps:
firstly, weighing raw materials according to the components and the using amount of the invention for later use;
secondly, all the raw materials are sequentially put into a mixer to be uniformly mixed, and the mixture is sealed for later use on the premise of no caking and solidification;
thirdly, putting the uniformly mixed composite powder into a vacuum drier for drying;
sampling to detect heavy metal and microbe;
detecting unqualified mixed materials, retreating according to reasons, and subpackaging qualified mixed materials;
sixthly, the subpackaged product enters an outer packing chamber for outer packing;
and seventhly, carrying out quality inspection on site, and warehousing after the quality inspection is qualified.
The invention relates to an eating method of a medicated diet for people with hyperlipidemia, which comprises the following steps:
soaking the product in warm water for 1 bag, stirring, and taking after appropriate temperature. 1 bag each time, 2 times daily.
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
The specific components and amounts of this example are as follows:
2000 parts of hawthorn, 1500 parts of sea buckthorn, 2000 parts of medlar, 1500 parts of astragalus, 1000 parts of chrysanthemum, 1500 parts of ginkgo, 1500 parts of purslane, 1500 parts of purple perilla, 2000 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1500 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1500 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
The preparation process of this example is as follows:
firstly, weighing raw materials according to the components and the using amount of the invention for later use;
secondly, all the raw materials are sequentially put into a mixer to be uniformly mixed, and the mixture is sealed for later use on the premise of no caking and solidification;
thirdly, putting the uniformly mixed composite powder into a vacuum drier for drying;
sampling to detect heavy metal and microbe;
detecting unqualified mixed materials, retreating according to reasons, and subpackaging qualified mixed materials;
sixthly, the subpackaged product enters an outer packing chamber for outer packing;
and seventhly, carrying out quality inspection on site, and warehousing after the quality inspection is qualified.
Example 2
The specific components and amounts of this example are as follows:
1800 parts of hawthorn, 1600 parts of sea buckthorn, 2100 parts of medlar, 1500 parts of astragalus, 1000 parts of chrysanthemum, 1500 parts of ginkgo, 1500 parts of purslane, 1500 parts of purple perilla, 2000 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1450 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1550 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
The procedure of this example was the same as in example 1.
Example 3
The specific components and amounts of this example are as follows:
1900 parts of hawthorn, 1600 parts of sea buckthorn, 2000 parts of medlar, 1500 parts of astragalus, 1000 parts of chrysanthemum, 1500 parts of ginkgo, 1500 parts of purslane, 1600 parts of purple perilla, 1800 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1500 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1600 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
The procedure of this example was the same as in example 1.
Example 4
The specific components and amounts of this example are as follows:
1950 parts of hawthorn, 1500 parts of sea buckthorn, 1800 parts of medlar, 1500 parts of astragalus, 1100 parts of chrysanthemum, 1500 parts of ginkgo, 1600 parts of purslane, 1550 parts of purple perilla, 2000 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1500 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1500 parts of soybean lecithin, 750 parts of vitamin C and 250 parts of vitamin E.
The procedure of this example was the same as in example 1.
Example 5
The specific components and amounts of this example are as follows:
1850 parts of hawthorn, 1500 parts of sea buckthorn, 1850 parts of medlar, 1500 parts of astragalus, 1150 parts of chrysanthemum, 1500 parts of ginkgo, 1550 parts of purslane, 1600 parts of purple perilla, 1800 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1600 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1600 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
The procedure of this example was the same as in example 1.
Example 6
The specific components and amounts of this example are as follows:
2000 parts of hawthorn, 1550 parts of sea buckthorn, 1800 parts of wolfberry fruit, 1500 parts of astragalus, 1050 parts of chrysanthemum, 1500 parts of ginkgo seed, 1550 parts of purslane, 1550 parts of purple perilla, 1850 parts of red yeast rice, 1550 parts of alpha-linolenic acid, 1550 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1550 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
The procedure of this example was the same as in example 1.
Clinical trial
Case 1: hyperlipidemia
Patient name: zhao something
Age: age 70
Sex: for male
Occupation: retire
Hospital diagnosis: hyperlipidemia
Before the present invention is taken, the results of blood fat inspection show that the values of triglyceride, total cholesterol and low density lipoprotein are all higher. After the traditional Chinese medicine is taken for 50 days, the total cholesterol and the low-density lipoprotein are reduced to normal ranges in the blood fat inspection result except that the triglyceride is slightly higher.
Case 2: hyperlipidemia
Patient name: one on another
Age: age 66 years old
Sex: woman
Occupation: is free of
Hospital diagnosis: hyperlipidemia
Before the present invention is taken, the results of four tests of blood fat (triglyceride, total cholesterol, low density lipoprotein and high density lipoprotein) show that the values of triglyceride, total cholesterol and low density lipoprotein are all higher. After the invention is taken for 30 days, triglyceride is reduced, and total cholesterol and low density lipoprotein are reduced to normal range.
Case 3: hyperlipidemia
Patient name: something in the poplar
Age: 71 years old
Sex: for male
Occupation: retire
Hospital diagnosis: hyperlipidemia
Before the present invention is taken, the results of blood fat inspection show that the values of triglyceride, total cholesterol and low density lipoprotein are all higher. After the invention is taken for 30 days, triglyceride is reduced, and total cholesterol and low density lipoprotein are reduced to normal range.
The invention discloses a medicated diet for people with hyperlipidemia, which can be realized by appropriately improving process parameters by the technical personnel in the field with reference to the contents in the text. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the invention has been described in terms of preferred embodiments, it will be apparent to those skilled in the art that the technology can be practiced and applied by modifying or appropriately combining the products described herein without departing from the spirit and scope of the invention.

Claims (2)

1. The medicated diet for people with hyperlipidemia is characterized by comprising the following components in parts by weight:
1000-5000 parts of hawthorn, 1000-3000 parts of sea buckthorn, 1000-5000 parts of wolfberry fruit, 1000-3000 parts of astragalus membranaceus, 1000-2000 parts of chrysanthemum, 1000-3000 parts of ginkgo seed, 1000-3000 parts of purslane, 1000-3000 parts of purple perilla, 1000-5000 parts of red yeast rice, 1000-3000 parts of alpha-linolenic acid, 1000-3000 parts of conjugated linoleic acid, 5000-10000 parts of soybean protein, 1000-3000 parts of soybean lecithin, 500-1000 parts of vitamin C and 200-500 parts of vitamin E.
2. The medicated diet as claimed in claim 1, which comprises the following components in parts by weight:
2000 parts of hawthorn, 1500 parts of sea buckthorn, 2000 parts of medlar, 1500 parts of astragalus, 1000 parts of chrysanthemum, 1500 parts of ginkgo, 1500 parts of purslane, 1500 parts of purple perilla, 2000 parts of red yeast rice, 1500 parts of alpha-linolenic acid, 1500 parts of conjugated linoleic acid, 5000 parts of soybean protein, 1500 parts of soybean lecithin, 700 parts of vitamin C and 300 parts of vitamin E.
CN202110611871.7A 2021-06-02 2021-06-02 Medicated diet for people with hyperlipidemia Pending CN113244367A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110611871.7A CN113244367A (en) 2021-06-02 2021-06-02 Medicated diet for people with hyperlipidemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110611871.7A CN113244367A (en) 2021-06-02 2021-06-02 Medicated diet for people with hyperlipidemia

Publications (1)

Publication Number Publication Date
CN113244367A true CN113244367A (en) 2021-08-13

Family

ID=77185932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110611871.7A Pending CN113244367A (en) 2021-06-02 2021-06-02 Medicated diet for people with hyperlipidemia

Country Status (1)

Country Link
CN (1) CN113244367A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113331415A (en) * 2021-06-02 2021-09-03 膳行天下(吉林)科技发展有限公司 Medicated diet for people with sleep disorder

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1389263A (en) * 2002-07-09 2003-01-08 中国科学院武汉植物研究所 Compound ginkgo capsule
CN1449816A (en) * 2003-05-09 2003-10-22 内蒙古复旦蒙耀生物技术有限责任公司 Pharmaceutics for regulating blood-lipid and protecting liver and preparation process thereof
CN101091708A (en) * 2006-06-22 2007-12-26 沈阳东宇药业有限公司 Composition for reducing blood fat, and preparation method
CN101142989A (en) * 2007-11-02 2008-03-19 于文英 Technology for preparing soybean protein deep processing food
CN101507494A (en) * 2009-02-12 2009-08-19 刘志伟 Special diet food for patient with hyperlipidemia and hypertension
CN101756227A (en) * 2008-10-30 2010-06-30 乔振伟 Chinese wolfberry health tea and processing method thereof
CN102754890A (en) * 2012-07-27 2012-10-31 青海万福康药业有限公司 Wolfberry sea-buckthorn solid particle beverage and producing method thereof
CN103190625A (en) * 2013-04-16 2013-07-10 山西金科海生物科技有限公司 Seabuckthorn phyllanthus chrysanthemum composite concentrated solution diet therapy product for regulating blood lipid, reducing blood viscosity, and increasing cardiac muscle blood supply
CN103445146A (en) * 2012-05-30 2013-12-18 苏州法莫生物技术有限公司 Health food having function of adjusting blood lipid
CN104544061A (en) * 2014-12-23 2015-04-29 山东世纪春食品有限公司 Food for special dietary use for hyperlipidemia patients to eat
CN105727270A (en) * 2016-04-26 2016-07-06 德立唯（北京）生物科技有限公司 Composition capable of increasing high-density lipoprotein and preventing and treating atherosclerosis and preparing method and application thereof
CN108837036A (en) * 2018-08-03 2018-11-20 威海康博尔生物药业有限公司 A kind of blood fat-reducing blood pressure-decreasing, the preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof
CN111034887A (en) * 2018-10-14 2020-04-21 黄晓弟 Red yeast rice vinegar beverage and preparation method thereof

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1389263A (en) * 2002-07-09 2003-01-08 中国科学院武汉植物研究所 Compound ginkgo capsule
CN1449816A (en) * 2003-05-09 2003-10-22 内蒙古复旦蒙耀生物技术有限责任公司 Pharmaceutics for regulating blood-lipid and protecting liver and preparation process thereof
CN101091708A (en) * 2006-06-22 2007-12-26 沈阳东宇药业有限公司 Composition for reducing blood fat, and preparation method
CN101142989A (en) * 2007-11-02 2008-03-19 于文英 Technology for preparing soybean protein deep processing food
CN101756227A (en) * 2008-10-30 2010-06-30 乔振伟 Chinese wolfberry health tea and processing method thereof
CN101507494A (en) * 2009-02-12 2009-08-19 刘志伟 Special diet food for patient with hyperlipidemia and hypertension
CN103445146A (en) * 2012-05-30 2013-12-18 苏州法莫生物技术有限公司 Health food having function of adjusting blood lipid
CN102754890A (en) * 2012-07-27 2012-10-31 青海万福康药业有限公司 Wolfberry sea-buckthorn solid particle beverage and producing method thereof
CN103190625A (en) * 2013-04-16 2013-07-10 山西金科海生物科技有限公司 Seabuckthorn phyllanthus chrysanthemum composite concentrated solution diet therapy product for regulating blood lipid, reducing blood viscosity, and increasing cardiac muscle blood supply
CN104544061A (en) * 2014-12-23 2015-04-29 山东世纪春食品有限公司 Food for special dietary use for hyperlipidemia patients to eat
CN105727270A (en) * 2016-04-26 2016-07-06 德立唯（北京）生物科技有限公司 Composition capable of increasing high-density lipoprotein and preventing and treating atherosclerosis and preparing method and application thereof
CN108837036A (en) * 2018-08-03 2018-11-20 威海康博尔生物药业有限公司 A kind of blood fat-reducing blood pressure-decreasing, the preparation for preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof
CN111034887A (en) * 2018-10-14 2020-04-21 黄晓弟 Red yeast rice vinegar beverage and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
沈丕安 编著: "《中药药理学与临床运用（上册）》", 30 June 2020, 吉林科学技术出版社 *
程嘉艺 主编: "《药食同源中药材药理研究与应用》", 31 March 2018, 辽宁科学技术出版社 *
郑建仙 主编: "《功能性食品学（第三版）"》", 30 November 2019, 中国纺织出版社有限公司 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113331415A (en) * 2021-06-02 2021-09-03 膳行天下(吉林)科技发展有限公司 Medicated diet for people with sleep disorder

Similar Documents

Publication Publication Date Title
CN105995720A (en) Enzyme Laiyang pear paste and preparation method and application thereof
CN106214989A (en) A kind of defying age, the deer's blood health-care medicated wine improving memory and preparation method thereof
CN102920806B (en) Nerve-soothing blood-pressure-reducing traditional Chinese medicine tea
CN108835638A (en) A kind of Soboring-up liver-protecting improves the food and preparation method thereof of immunity
CN111110792A (en) Rhizoma polygonati and ginseng tea for controlling sugar, regulating lipid, reducing viscosity, preventing and treating diabetes and complications thereof
CN113244367A (en) Medicated diet for people with hyperlipidemia
Kleiner The true nature of herbs
CN106418143A (en) Composition for improving sleep and vision and application thereof
CN110559389A (en) traditional Chinese medicine wine for treating hyperuricemia, gout and rheumatism and preparation method thereof
CN104388263A (en) Hawthorn/longan health-preserving traditional Chinese medicine wine and preparation method thereof
CN108478714A (en) A kind of paediatrics self-closing disease rehabilitation auxiliary Chinese medicine composition
CN107927279A (en) A kind of health protection tea for treating cardiovascular and cerebrovascular disease and preparation method thereof
CN112089784A (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis
CN111870630A (en) Medicine formula for enhancing resistance and immunity and preparation process
CN1660207A (en) Preparation of health care for reducing blood fat and cholesterol, and producing method
CN109602867A (en) A kind of gout tea and preparation method thereof
CN108355029A (en) It is a kind of to treat the drug and preparation method thereof vomitted after chemicotherapy
CN103520644B (en) Traditional Chinese medicine composition used for treating phlegm stagnation type hyperlipidaemia and preparation method of composition
CN108004090A (en) A kind of healthy medicated wine and preparation method thereof
CN106728828A (en) A kind of Chinese medicine preparation and its preparation technology for treating coronary heart disease
CN101164595A (en) Traditional Chinese medicine for curing anorexia
CN106665776A (en) Traditional Chinese medicine pastries for conditioning yin deficiency constitutions
CN106221994A (en) Utilize the process of Chinese herbal medicine brewing health-care wine
CN113679793A (en) Lipid-lowering liver-protecting tea and preparation method thereof
CN105832867A (en) Soaking method of pepper and centipede selenium-rich medicinal liquor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220801

Address after: 130000 group 7, Da Shi Jia Wo Bao Tun, Chengguang village, Changde street, Kuancheng District, Changchun City, Jilin Province

Applicant after: Zhao Tian

Address before: 130000 room 1001, building 23, Zone G, phase II, blue harbor, No. 759, Huigong Road, Erdao District, Changchun City, Jilin Province

Applicant before: Shanxingtianxia (Jilin) Technology Development Co.,Ltd.

TA01 Transfer of patent application right
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210813

WD01 Invention patent application deemed withdrawn after publication